ReadYourDNA

Zidovudine (Retrovir)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Zidovudine

What it is

Zidovudine (AZT) was the first HIV medicine, approved in 1987: a nucleoside reverse transcriptase inhibitor that is built into viral DNA and stops it from growing. It is now used mainly to prevent HIV passing from mother to baby around birth, and in some combinations; anaemia and other side effects have limited its use elsewhere. It is sold as Retrovir, among other names.

How genes come into it

Zidovudine is cleared mainly by UGT2B7, which joins it to glucuronic acid, and it is activated inside cells by kinases. Studies have looked at UGT2B7 and at the transporters ABCC1, ABCC4 and ABCB1 for its levels and response. The findings come from a few studies, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Zidovudine. Upload your DNA file to see which of these rows apply to you.

Rated evidence (3 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

UGT2B7 rs28365062: Level 3. Other. 1.

ABCC4 rs11568695: Level 3. Other: HIV infectious disease. 1.

ABCC1 rs212091: Level 3. Efficacy: HIV infectious disease. 1.

Metabolism (1 finding)

Studies of how quickly the body processes this medication.

UGT2B7 rs28365062: Allele G is associated with increased metabolism of zidovudine as compared to allele A.

Response (7 findings)

Studies of how well it worked in people carrying a variant.

ABCC1 rs212091: Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.

ABCB1 rs2032582: Allele A is associated with response to lamivudine, nevirapine or zidovudine in people with HIV Infections as compared to allele C.

ABCB1 rs3842: Allele C is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele T.

ABCC1 rs3743527: Allele T is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele C.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Emtriva (NRTIs)

Epivir (NRTIs)

NRTIs (class) (NRTIs)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com